[1]童玲玲,林燕妮,朱健清,等.发病4.5~6 h急性脑梗死尿激酶溶栓疗效和安全性分析[J].医学信息,2024,37(07):98-101.[doi:10.3969/j.issn.1006-1959.2024.07.018]
　TONG Ling-ling,LIN Yan-ni,ZHU Jian-qing,et al.Analysis of Efficacy and Safety on Urokinase Thrombolysis in Acute Cerebral Infarction at 4.5-6 h of Onset[J].Journal of Medical Information,2024,37(07):98-101.[doi:10.3969/j.issn.1006-1959.2024.07.018]
点击复制

发病4.5~6 h急性脑梗死尿激酶溶栓疗效和安全性分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年07期
页码:
98-101
栏目:
论著
出版日期:
2024-04-01

文章信息/Info

Title:
Analysis of Efficacy and Safety on Urokinase Thrombolysis in Acute Cerebral Infarction at 4.5-6 h of Onset
文章编号:
1006-1959（2024）07-0098-04
作者:
童玲玲; 林燕妮; 朱健清; 等
（玉林市第一人民医院/广西医科大学第六附属医院神经内科，广西 玉林 537000）
Author(s):
TONG Ling-ling; LIN Yan-ni; ZHU Jian-qing; et al.
(Department of Neurology,the First People’s Hospital of Yulin City/the Sixth Affiliated Hospital of Guangxi Medical University,Yulin 537000,Guangxi,China)
关键词:
急性脑梗死; 尿激酶; 溶栓; 意识障碍; 血糖; 症状性颅内动脉狭窄; 发病-治疗时间
Keywords:
Acute cerebral infarction; Urokinase; Thrombolysis; Consciousness disorder; Blood glucose; Symptomatic intracranial artery stenosis; Onset to treatment time
分类号:
R743.33
DOI:
10.3969/j.issn.1006-1959.2024.07.018
文献标志码:
A
摘要:
目的 探讨发病4.5~6 h急性脑梗死（ACI）患者尿激酶（UK)溶栓疗效和安全性。方法 回顾性分析2020年1月-2022年12月我院收治的128例ACI患者临床资料。根据出院时改良Rankin评分量表（mRS）结果分为预后良好组（mRS≤2分，n=78）和预后不良组（mRS＞2分，n=50）。比较两组临床资料，多因素Logistic分析影响患者预后的危险因素。结果 两组意识障碍、血糖控制不佳、症状性颅内动脉狭窄及发病至治疗时间（OTT）比较，差异有统计学意义（P＜0.05）；Logistic分析显示，意识障碍、血糖控制不佳及OTT均是导致ACI患者预后不良的因素。ACI患者的出入院mRS比较，差异有统计学意义（P＜0.05）。结论 ACI发病4.5~6 h的患者进行UK溶栓能明显改善神经功能和减轻致残率，且出血风险低，无严重并发症，相对安全。
Abstract:
Objective To investigate the efficacy and safety of urokinase (UK) thrombolysis in patients with acute cerebral infarction (ACI) 4.5-6 h after onset.Methods The clinical data of 128 patients with ACI admitted to our hospital from January 2020 to December 2022 were retrospectively analyzed. According to the results of modified Rankin scale (mRS) at discharge, the patients were divided into good prognosis group (mRS≤2 scores, n=78) and poor prognosis group (mRS>2 scores, n=50). The clinical data of the two groups were compared, and the risk factors affecting the prognosis of patients were analyzed by multivariate Logistic analysis.Results There were significant differences in disturbance of consciousness, poor blood glucose control, symptomatic intracranial artery stenosis and onsetto treatment time (OTT) between the two groups (P<0.05). Logistic analysis showed that disturbance of consciousness, poor blood glucose control and OTT were all factors leading to poor prognosis in ACI patients. There was a statistically significant difference in mRS between admission and discharge of ACI patients(P<0.05).Conclusion UK thrombolysis in patients with ACI at 4.5-6 h can significantly improve neurological function and reduce disability rate, with low risk of bleeding, no serious complications, and relatively safe.

参考文献/References:

[1]Phipps MS,Cronin CA.Management of acute ischemic stroke[J].BMJ,2020,368:l6983.[2]Gao L,Zhang S,Wo X,et al.Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction[J].Pakistan Journal of Medical Sciences,2022,38(3):498-504.[3]Khatri P,Yeatts SD,Mazighi M,et al.Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS Ⅲ) phase 3 trial[J].Lancet Neurol,2014,13(6):567-574.[4]中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018,51(9):666-682.[5]Sun F,Liu H,Fu HX,et al.Comparative study of intravenous thrombolysis with rt-PA and urokinase for patients with acute cerebral infarction[J].J Int Med Res,2020,48(5):300060519895352.[6]Zeng J,Wang F,Feng H,et al.Influencing Factors of Recanalization after Intravenous Thrombolysis with Urokinase in Acute Cerebral Infarction Patients[J].Eur Neurol,2020,83(2):162-166.[7]Liu J,Tian L,Li N.Treatment efficacy of arterial urokinase thrombolysis combined with mechanical thrombectomy for acute cerebral infarction and its influence on neuroprotective factors and factors for neurological injury[J].Am J Transl Res,2021,13(4):3380-3389.[8]Zeng J,Chen F,Chen Y,et al.Predictors of hemorrhagic complications after intravenous thrombolysis in acute cerebral infarction patients: A single-center study of 391 cases[J].Medicine (Baltimore),2021,100(37):e27053.[9]Alali RA.A short review of proprotein convertase subtilisin/kexin type 9 inhibitors[J].Rev Cardiovasc Med,2019,20(1):1-8.[10]Sepp D,Franz D,Triftshaeuser N,et al.Mobilization of CD133+ progenitor cells in patients with acute cerebral infarction[J].PLoS One,2014,9(3):e70796.[11]Berge E,Whiteley W,Audebert H,et al.European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke[J].Eur Stroke J,2021,6(1):1101-1103.[12]刘凯,王伊龙,李子孝,等.尿激酶静脉溶栓治疗急性缺血性卒中/短暂性脑缺血发作的院内死亡率及相关影响因素的多中心分析[J].中国卒中杂志,2020,15(10):1078-1082.[13]Bao H,Gao HR,Pan ML,et al.Comparative study on the efficacy and safety of alteplase and urokinase in the treatment of acute cerebral infarction[J].Technology and Health Care,2021,29(1):85-90.[14]李明.尿激酶静脉溶栓治疗急性脑梗死的临床效果[J].临床合理用药杂志,2021,14(29):35-37.[15]李振华,杨清成,张建刚,等.尿激酶溶栓后序贯应用注射用丹参多酚酸治疗急性缺血性脑卒中的疗效及安全性分析[J].药物评价研究,2021,44(11):2469-2474.[16]国家“九五”攻关课题协作组.急性脑梗死六小时以内的静脉溶栓治疗[J].中华神经科杂志,2002,35(4):210-213.[17]国家“九五”攻关课题协作组.急性脑梗死(6h以内)静脉溶栓治疗[J].中风与神经疾病杂志,2001,18(5):259-261.[18]Berge E,Whiteley W,Audebert H,et al.European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke[J].European Stroke Journal,2021,6(1):Ⅰ-LⅫ.[19]赵辉,张燕,井含君,等.rt-PA与尿激酶静脉溶栓治疗不同时问窗急性脑梗死的临床疗效及预后观察[J].贵州医药,2022,46(8):1212-1214.

相似文献/References:

[1]冯 湧.新一代抗凝血药阿加曲班的临床应用进展[J].医学信息,2018,31(02):43.[doi:10.3969/j.issn.1006-1959.2018.02.015]
　FENG Yong.Progress in Clinical Application of the New Generation Anticoagulant Agatripine[J].Journal of Medical Information,2018,31(07):43.[doi:10.3969/j.issn.1006-1959.2018.02.015]
[2]王 伟,宫秀群,余 亮.阿替普酶治疗急性脑梗死患者临床转归的影响因素[J].医学信息,2022,35(11):84.[doi:10.3969/j.issn.1006-1959.2022.11.022]
　WANG Wei,GONG Xiu-qun,YU Liang.The Influencing Factors of Clinical Outcome in Patients with Acute Cerebral Infarction Treated with Alteplase[J].Journal of Medical Information,2022,35(07):84.[doi:10.3969/j.issn.1006-1959.2022.11.022]
[3]陈建新.阿加曲班注射液治疗急性脑梗死的疗效及对血清VEGF、GLUT-1水平的影响[J].医学信息,2018,31(19):5.[doi:10.3969/j.issn.1006-1959.2018.19.002]
　CHEN Jian-xin.Effect of Argatroban Injection on Acute Cerebral Infarction and Its Effect on Serum VEGF and GLUT-1 Levels[J].Journal of Medical Information,2018,31(07):5.[doi:10.3969/j.issn.1006-1959.2018.19.002]
[4]刘 然.头颅MRI-DWI病灶数量及部位对脑梗死复发预测意义[J].医学信息,2018,31(22):172.[doi:10.3969/j.issn.1006-1959.2018.22.052]
　LIU Ran.The Significance of the Number and Location of MRI-DWI Lesions in Predicting the Recurrence of Cerebral Infarction[J].Journal of Medical Information,2018,31(07):172.[doi:10.3969/j.issn.1006-1959.2018.22.052]
[5]褚春沐.阿加曲班联合阿替普酶静脉溶栓治疗急性脑梗死的效果及对脑血管储备功能的影响[J].医学信息,2022,35(13):133.[doi:10.3969/j.issn.1006-1959.2022.13.031]
　CHU Chun-mu.Effect of Argatroban Combined with Alteplase Intravenous Thrombolysis on Acute Cerebral Infarction and its Effect on Cerebrovascular Reserve Function[J].Journal of Medical Information,2022,35(07):133.[doi:10.3969/j.issn.1006-1959.2022.13.031]
[6]徐润鸿.血府逐瘀汤联合阿托伐他汀钙治疗急性脑梗死的临床观察[J].医学信息,2019,32(05):165.[doi:10.3969/j.issn.1006-1959.2019.05.054]
　XU Run-hong.Clinical Observation on Treatment of Acute Cerebral Infarction with Xuefu Zhuyu Decoction Combined with Atorvastatin Calcium[J].Journal of Medical Information,2019,32(07):165.[doi:10.3969/j.issn.1006-1959.2019.05.054]
[7]王丹丹,王学建.动脉自旋标记在急性脑梗死中的应用[J].医学信息,2019,32(12):102.[doi:10.3969/j.issn.1006-1959.2019.12.031]
　WANG Dan-dan,WANG Xue-jian.Application of Arterial Spin Labeling in Acute Cerebral Infarction[J].Journal of Medical Information,2019,32(07):102.[doi:10.3969/j.issn.1006-1959.2019.12.031]
[8]赵宏伟.急性脑梗死的危险因素及临床诊治研究[J].医学信息,2019,32(18):44.[doi:10.3969/j.issn.1006-1959.2019.17.015]
　ZHAO Hong-wei.Risk Factors and Clinical Diagnosis and Treatment of Acute Cerebral Infarction[J].Journal of Medical Information,2019,32(07):44.[doi:10.3969/j.issn.1006-1959.2019.17.015]
[9]陶 林,马 婷.丁苯酞注射液、胶囊序贯疗法辅治急性进展性脑梗死的 疗效及其对神经功能的影响[J].医学信息,2019,32(18):135.[doi:10.3969/j.issn.1006-1959.2019.18.045]
　TAO Lin,MA Ting.Efficacy of Butylphthalide Injection and Capsule Sequential Therapy in the Treatment of Acute Progressive Cerebral Infarction and Its Effect on Neurological Function[J].Journal of Medical Information,2019,32(07):135.[doi:10.3969/j.issn.1006-1959.2019.18.045]
[10]朱丽娜,王宗立,顾萌萌.UA、Hcy和FIB与颈动脉粥样硬化斑块及 脑梗死关系的分析[J].医学信息,2019,32(18):173.[doi:10.3969/j.issn.1006-1959.2019.18.061]
　ZHU Li-na,WANG Zong-li,GU Meng-meng.Analysis of the Relationship Among UA, Hcy，FIB and Carotid Atherosclerotic Plaque， Cerebral Infarction[J].Journal of Medical Information,2019,32(07):173.[doi:10.3969/j.issn.1006-1959.2019.18.061]

更新日期/Last Update: 1900-01-01